Address: Przedstawicielstwo w Polsce
ul. Otrebuska 15
01475 Warszawa,Poland
Tel: +48 228 637 281
Web: http://www.woerwagpharma.com/
For 40 years WÖRWAG Pharma stands for competence and expertise in the fields of biofactors and generics. We have established our reputation here as a specialist in the treatment of diabetes and its accompanying disorders.
WÖRWAG Pharma offers customised products for diabetics with their accompanying disorders – from prevention to therapy.
Benfotiamine. An active substance discovered by Japanese researchers 60 years ago in their search for a treatment for Vitamin B1 deficiency. Dr. Fritz Wörwag, the founder of the company, soon realized the special importance of Benfothiamine within diabetes therapy and the treatment of polyneuropathies. And with this he showed a future-oriented perspective and confirmed the medicinal expertise of the company which he founded.
The biofactors sector and the field of diabetes with its accompanying disorders remain at the heart of the WÖRWAG product range. Products such as thiogamma or milgamma, two examples from the extensive portfolio document the decades of expert knowledge in this field: the medications act causatively and gently against neuropathies.
Benfotiamine effectively corrects the Vitamin B 1 deficiencies which are common particularly in diabetics. This substance – based on the most recent scientific knowledge – is even expected to provide all-round protection for these patients.
Other biofactors from the WÖRWAG house protect the heart and circulatory system (Magnerot), correct zinc deficiencies (Zinkorot) or deficiencies of folic acid, Vitamin B 12 and iron (Ferro-Folgamma). The “gamma” series of generics also ensures cost awareness in physicians and patients.
Biofactors, preparations for polyneuropathy and generics with excellent cost-benefit ratios add up to the broad product range of WÖRWAG Pharma.
Norina Alinta Gavan, CEO of Wörwag Pharma Romania, reveals how the affiliate will become more active and entrepreneurial with the change in shareholding while having an increased responsibility for the…
Milica Glisic, with over 15 years of experience in the pharma business and ten years at Wörwag Pharma, discusses the strong workforce in the Balkans, Wörwag Pharma’s mission in the…
Ivan Kolev, country manager at Wörwag Pharma Bulgaria, explains how has the affiliate performed over the last years as well as shares an overview about the development of diabetes and…
Victoria Tarabanova, country manager of the Ukrainian office of Wörwag Pharma, a company dedicated to treating diabetic comorbidities such as neuropathic, cardiovascular and neurological diseases, provides insights into the company’s…
The general manager of Wörwag Pharma Czech Republic & Slovakia reviews to what degree the Czech and Slovak market are homogeneous and which strategies can be successfully transferred from one…
The managing director of Wörwag Pharma Hungary, Dr. Éva Kádár depicts the company’s impressive evolution, highlighting the expansive network of neuropathy centers that they’ve helped establish all over Hungary and…
Some of the biggest stories coming out of the Central and Eastern European (CEE) region’s pharma industry, including the European Bank’s EUR 25 million investment in Pelion Group; the amendments…
With a geostrategic location and easy access to both Western Europe and the rest of the emerging Central and Eastern Europe (CEE) region, Poland represents the sixth largest pharma market…
Poland’s largest pharmaceutical company and leading generics manufacturer, Polpharma, is looking to expand its presence outside of the country’s borders. With a recent acquisition bid for former Sanofi European generics…
Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Polpharma’s bid for Zentiva, Richter’s acquisition of OC Distributors and MDD approval…
Some of the top stories emanating from Poland’s pharma industry, including Polish biotech Ryvu Therapeutics’ exclusive deal with Exelixis, the partnership between Polpharma and startup Pikralida on a promising epilepsy…
Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Poland’s most promising biotech start-ups, an interview with Zentiva CEO Nick Haggar,…
Every year, Polish news magazine Wprost publishes its ranking of the top 200 Polish companies across all industries. Here, we profile the top five pharma-related companies featured in the 2019 rankings.…
Reinier Schlatmann, Philips CEO in Central and Eastern Europe, talks about the strategic significance of Poland for the company and how the implementation of Philips’ strategy and its focus on…
Ewa Sek, general manager at ResMed Poland, explains the crucial role of ResMed in raising awareness on sleep apnea, COPD and other respiratory-related conditions in Poland and highlights the important…
Jan Kruk of Polish pharmaceutical logistics and distribution specialist, Cefarm, discusses the organization’s secrets of success, as well as the broader logistics and distribution landscape in Poland. As the president…
Arjo, formerly Arjo Huntleigh, has undergone a rebrand and established its first formal office in Poland in 2017. Konrad Pianko, president of the CEE region which includes over 22 countries,…
Dariusz Adamusiński, general manager of A&D Pharma’s Polish operations has a busy year ahead. A new warehouse in Poland, partnerships across the pharmaceutical spectrum coupled with new regulations are all…
See our Cookie Privacy Policy Here
